Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isosorbide oral solution is a small molecule osmotic diuretic being developed by Lunan Better Pharmaceutical Co., Ltd. for the treatment of Meniere's disease. The drug's primary mechanism of action involves reducing endolymphatic hydrops, a pathological buildup of fluid in the inner ear that is a hallmark of Meniere's disease. By acting as an osmotic agent, isosorbide facilitates the withdrawal of excess fluid from the endolymphatic space. While isosorbide has a long history of use for this indication in countries like Japan, this specific formulation is undergoing a formal Phase II/III clinical program to establish its efficacy and safety profile in patients with unilateral Meniere's disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Isosorbide oral solution (Lunan Better Pharmaceutical).